Drug Information

Drug General Information
Drug ID
D0A7NB
Former ID
DCL000985
Drug Name
Siplizumab
Synonyms
Siplizumab (USAN/INN)
Drug Type
Antibody
Indication Lymphoma [ICD9: 202.8, 208.9; ICD10:C81-C86] Phase 2 [531024]
Cancer; Psoriasis [ICD9: 140-229, 696; ICD10:L40] Discontinued in Phase 2 [536054]
Company
Medlmmune; AstraZeneca
CAS Number
CAS 288392-69-8
PubChem Substance ID
47207508
Target and Pathway
Target(s) T-cell surface antigen CD2 Target Info [536054]
KEGG Pathway Cell adhesion molecules (CAMs)
Hematopoietic cell lineage
NetPath Pathway TCR Signaling Pathway
IL2 Signaling Pathway
Reactome Cell surface interactions at the vascular wall
WikiPathways Cell surface interactions at the vascular wall
References
Ref 531024Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies.Int J Dermatol. 2010 Jul;49(7):818-28.
Ref 536054Emerging drugs for moderate-to-severe psoriasis. Expert Opin Emerg Drugs. 2005 Feb;10(1):35-52.
Ref 536054Emerging drugs for moderate-to-severe psoriasis. Expert Opin Emerg Drugs. 2005 Feb;10(1):35-52.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.